Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened

Puma Biotechnology, Inc. (NASDAQ:PBYI) shares crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $4.33 and traded as high as $4.99. Puma Biotechnology shares last traded at $4.96, with a volume of 315,611 shares.

Analyst Upgrades and Downgrades

PBYI has been the topic of a number of recent research reports. Weiss Ratings cut shares of Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. Wall Street Zen downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, Puma Biotechnology has an average rating of “Moderate Buy” and an average price target of $7.00.

Puma Biotechnology Trading Down 1.8%

The firm has a market capitalization of $249.94 million, a price-to-earnings ratio of 5.06 and a beta of 1.35. The business’s 50 day moving average price is $5.11 and its 200-day moving average price is $4.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.73 and a quick ratio of 1.62.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.12. Puma Biotechnology had a return on equity of 53.15% and a net margin of 20.38%.The company had revenue of $54.48 million for the quarter, compared to analyst estimates of $51.00 million. Puma Biotechnology has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities analysts forecast that Puma Biotechnology, Inc. will post 0.31 EPS for the current fiscal year.

Insider Buying and Selling at Puma Biotechnology

In related news, Director Michael Patrick Miller sold 20,000 shares of Puma Biotechnology stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $4.86, for a total value of $97,200.00. Following the sale, the director directly owned 54,000 shares in the company, valued at $262,440. The trade was a 27.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 23.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Puma Biotechnology

A number of hedge funds and other institutional investors have recently bought and sold shares of PBYI. Virtus Advisers LLC grew its stake in shares of Puma Biotechnology by 241.4% during the 3rd quarter. Virtus Advisers LLC now owns 47,172 shares of the biopharmaceutical company’s stock worth $250,000 after purchasing an additional 33,355 shares during the period. Sherbrooke Park Advisers LLC acquired a new stake in shares of Puma Biotechnology in the third quarter valued at about $162,000. Qube Research & Technologies Ltd boosted its holdings in Puma Biotechnology by 13.4% during the third quarter. Qube Research & Technologies Ltd now owns 155,516 shares of the biopharmaceutical company’s stock worth $826,000 after buying an additional 18,437 shares in the last quarter. Prelude Capital Management LLC grew its position in Puma Biotechnology by 15.0% during the third quarter. Prelude Capital Management LLC now owns 38,422 shares of the biopharmaceutical company’s stock worth $204,000 after buying an additional 5,000 shares during the period. Finally, Lazard Asset Management LLC purchased a new position in Puma Biotechnology in the third quarter valued at about $335,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.